Effect on Metabolic Parameters of Abilify in SPR

• Conditions: Schizophrenia; Metabolic Syndrome

• Registration Number: NCT00569764
• Lead Sponsor: Seoul National Hospital

Brief Summary

To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole

Detailed Description

To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia.

The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.

Study Timeline

• Study Start: 2007-12
• Study First Submitted: 2007-12-06
• Study First Submitted QC: 2007-12-06
• Study First Posted: 2007-12-07
• Status Verified: 2009-06
• Last Update Submitted: 2009-06-09
• Last Update Posted: 2009-06-12
• Study Completion: 2009-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• DSM-IV diagnosis with schizophrenia
• who signed an informed consent

Exclusion Criteria

• comorbid with substance abuse or substance dependence
• pregnancy or lactation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
weight lipid profile : HDL, LDL, total-cholesterol, triglyceride fasting blood glucose	1 year

Secondary Outcome Measures

Name	Time	Method
prolactin ECG	1 year

Trial Locations

Locations (1)

Seoul National Hospital; 🇰🇷 Seoul, Korea, Republic of